AtriCure, Inc. (ATRC) Reaches $17.41 After 3.00% Up Move; Xtant Medical Holdings (NYSEAMERICAN:XTNT) Shorts Decreased By 9.81%

February 15, 2018 - By Dolores Ford

Xtant Medical Holdings Incorporated (NYSEAMERICAN:XTNT) had a decrease of 9.81% in short interest. XTNT’s SI was 1.02M shares in February as released by FINRA. Its down 9.81% from 1.13 million shares previously. With 286,600 avg volume, 4 days are for Xtant Medical Holdings Incorporated (NYSEAMERICAN:XTNT)’s short sellers to cover XTNT’s short positions. The stock decreased 2.00% or $0.1 during the last trading session, reaching $4.68. About 22,942 shares traded or 33.91% up from the average. Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) has declined 75.28% since February 15, 2017 and is downtrending. It has underperformed by 91.98% the S&P500.

The stock of AtriCure, Inc. (NASDAQ:ATRC) is a huge mover today! The stock increased 4.13% or $0.69 during the last trading session, reaching $17.41. About 171,594 shares traded. AtriCure, Inc. (NASDAQ:ATRC) has risen 53.35% since February 15, 2017 and is uptrending. It has outperformed by 36.65% the S&P500.The move comes after 9 months positive chart setup for the $600.19M company. It was reported on Feb, 15 by Barchart.com. We have $17.93 PT which if reached, will make NASDAQ:ATRC worth $18.01M more.

Xtant Medical Holdings, Inc. develops, makes, and markets regenerative medicine products and devices in the United States and internationally. The company has market cap of $95.82 million. The Company’s biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. It currently has negative earnings. The firm also provides BacFast HD facet stabilization dowels; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; hMatrix dermal scaffold, an acellular matrix made from donated human dermal tissue that is used to replace a patientÂ’s damaged tissue; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone.

Among 9 analysts covering Atricure Inc. (NASDAQ:ATRC), 8 have Buy rating, 1 Sell and 0 Hold. Therefore 89% are positive. Atricure Inc. has $34 highest and $14 lowest target. $24.88’s average target is 42.91% above currents $17.41 stock price. Atricure Inc. had 30 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by Needham on Friday, July 28 with “Buy”. Piper Jaffray initiated AtriCure, Inc. (NASDAQ:ATRC) rating on Tuesday, May 30. Piper Jaffray has “Buy” rating and $2600 target. As per Thursday, November 2, the company rating was maintained by Needham. The firm has “Buy” rating by Dougherty & Company given on Tuesday, July 28. The stock of AtriCure, Inc. (NASDAQ:ATRC) earned “Buy” rating by Canaccord Genuity on Sunday, October 8. The firm earned “Buy” rating on Thursday, June 15 by Leerink Swann. The stock of AtriCure, Inc. (NASDAQ:ATRC) earned “Buy” rating by Canaccord Genuity on Thursday, July 27. As per Wednesday, July 29, the company rating was maintained by Needham. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, November 2. The stock has “Buy” rating by Needham on Tuesday, August 4.

AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company has market cap of $600.19 million. The firm offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It currently has negative earnings. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set.

Since August 21, 2017, it had 0 insider buys, and 1 sale for $224,000 activity. Shares for $224,000 were sold by Krell Elizabeth D on Monday, August 21.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: